Melanoma Clinical Trial

XTX101 Monotherapy and XTX101 and Pembrolizumab Combination Therapy in Patients With Advanced Solid Tumors

Summary

This is a first-in-human, Phase 1/2, multicenter, open-label study designed to evaluate the safety and tolerability of XTX101 as monotherapy and XTX101 and pembrolizumab combination therapy in patients with advanced solid tumors.

View Full Description

Full Description

This is a first-in-human, Phase 1/2, multicenter, open-label study designed to evaluate the safety and tolerability of XTX101, a tumor-selective anti-CTLA-4 antibody, as monotherapy and XTX101 and pembrolizumab combination therapy in patients with advanced solid tumors.

Part 1A will examine XTX101 monotherapy in an accelerated and standard 3+3 dose escalation design. Based on the results of Part 1A, patients with select advanced solid tumors will be enrolled in Part 1B, which will evaluate XTX101 monotherapy in relation to specific PD biomarkers.

Part 1C will examine XTX101 in combination with pembrolizumab in a standard 3+3 dose escalation design, examining up to 2 dose levels of XTX101 in combination with the labeled dose of pembrolizumab. After completion of Part 1C, the study will initiate Part 2, examining the RP2D of XTX101 and pembrolizumab combination therapy in patients with unresectable or metastatic melanoma.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Disease Criteria - Part 1A and 1C- Any histologically or cytologically confirmed solid tumor malignancy that is locally advanced or metastatic and has failed standard therapy, or standard therapy is not curative or available; Part 1B - Any histologically or cytologically confirmed solid tumor malignancy for which anti-PD-1 or anti-PD-L1 treatment is approved and has progressed on or after prior anti-PD-1 or anti-PD-L1 therapy. Part 2- histologically or cytologically confirmed unresectable or metastatic melanoma that has not been treated with prior anti-PD-1 or anti-PD-L1 therapy
ECOG performance status of 0 or 1
Adequate organ function
Part 2 only: measurable disease per iRECIST

Exclusion Criteria:

Received prior treatment with anti-CTL-4 therapy
Received prior immune-checkpoint therapy and experienced Grade 3 or greater toxicity lasting greater than 6 weeks
Received prior systemic anticancer therapy within 4 weeks prior to study treatment
Received prior radiotherapy within 2 weeks prior to study treatment
Has a diagnosis of immunodeficiency
Has known malignancy (other than disease under study) that is progressing or has required active treatment within the past 3 years
Has an active autoimmune disease that has required systemic treatment in past 2 years, including the use of disease modifying agents, corticosteroids or immunosuppressive drugs
Has an active infection requiring systemic therapy within 4 weeks prior to study treatment
Has a history of severe hypersensitivity reaction (≥ Grade 3) to any study intervention and/or any of its excipients
Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study
Part 2 only: has ocular melanoma
Part 2 only: has received prior anti-PD-1/L-1 therapy

Study is for people with:

Melanoma

Phase:

Phase 1

Estimated Enrollment:

144

Study ID:

NCT04896697

Recruitment Status:

Recruiting

Sponsor:

Xilio Development, Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 10 Locations for this study

See Locations Near You

California Cancer Associates for Research and Excellence, cCARE
Encinitas California, 92024, United States More Info
Christina Spencer
Contact
760-452-3909
[email protected]
Alberto Bessudo, MD
Principal Investigator
California Cancer Associates for Research and Excellence, cCARE
San Marcos California, 92069, United States More Info
Christina Spencer
Contact
760-452-3909
[email protected]
Alberto Bessudo, MD
Principal Investigator
Sarah Cannon Research Institute at Florida Cancer Specialists
Orlando Florida, 32827, United States More Info
Cesar Perez, M.D.
Contact
689-216-8500
[email protected]
Massachusetts General Hospital
Boston Massachusetts, 02114, United States More Info
Howard Kaufman, MD
Contact
617-724-4000
[email protected]
Carolina BioOncology Institute
Huntersville North Carolina, 28078, United States More Info
Ashley McClain Wallace
Contact
980-441-1021
[email protected]
John Powderly, MD
Principal Investigator
University of Pittsburgh Medical Center- Hillman Cancer Center
Pittsburgh Pennsylvania, 15232, United States More Info
Aubrey Murano
Contact
412-623-5503
[email protected]
Diwakar Davar, MD
Principal Investigator
Next Oncology
Austin Texas, 78758, United States More Info
Cynthia DeLeon
Contact
210-580-9521
[email protected]
Andrae Vandross, MD
Principal Investigator
Mary Crowley Cancer Research
Dallas Texas, 75230, United States More Info
Douglas Orr, MD
Contact
972-566-3000
[email protected]
Douglas Orr, MD
Principal Investigator
Tranquil Clinical Research
Webster Texas, 77598, United States More Info
Deborah Bates
Contact
[email protected]
John Knecht, MD
Principal Investigator
NEXT Virginia
Fairfax Virginia, 22031, United States More Info
Malaika Komtangi
Contact
210-580-9500
[email protected]
Alexander Spira, MD
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Melanoma

Phase:

Phase 1

Estimated Enrollment:

144

Study ID:

NCT04896697

Recruitment Status:

Recruiting

Sponsor:


Xilio Development, Inc.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.